Elizabeth Garrett-Mayer to Quinolones
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Quinolones.
Connection Strength
0.510
-
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. 2008 May 15; 14(10):3077-82.
Score: 0.283
-
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012 Jan 05; 119(1):55-63.
Score: 0.090
-
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2009 May 14; 113(20):4841-52.
Score: 0.074
-
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood. 2007 Feb 15; 109(4):1387-94.
Score: 0.064